GlobeNewswire by notified

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Share

Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar
2 Reason for the notification
a)Position/statusExecutive Vice President
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

Identification codeNovo Nordisk B DK0062498333
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







Price(s)Volume(s)
DKK 900.05178 shares
d)Aggregated information
  • Aggregated volume
  • Price


178 shares
DKK 160,208.90
e)Date of the transaction2024-05-02
f)Place of the transactionAQUIS EXCHANGE EUROPE AUCTION ON DEMAND (AOD)


Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar
2 Reason for the notification
a)Position/statusExecutive Vice President
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

Identification codeNovo Nordisk B DK0062498333
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







Price(s)Volume(s)
DKK 900.7410,128 shares
d)Aggregated information
  • Aggregated volume
  • Price


10,128 shares
DKK 9,122,689.30
e)Date of the transaction2024-05-02
f)Place of the transactionAQUIS EXCHANGE EUROPE NON DISPLAY ORDER BOOK (NDOB)


Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar
2 Reason for the notification
a)Position/statusExecutive Vice President
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

Identification codeNovo Nordisk B DK0062498333
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







Price(s)Volume(s)
DKK 900.172,253 shares
d)Aggregated information
  • Aggregated volume
  • Price


2,253 shares
DKK 2,028,089.70
e)Date of the transaction2024-05-02
f)Place of the transactionAQUIS EXCHANGE EUROPE


Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar
2 Reason for the notification
a)Position/statusExecutive Vice President
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

Identification codeNovo Nordisk B DK0062498333
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







Price(s)Volume(s)
DKK 900.1018,153 shares
d)Aggregated information
  • Aggregated volume
  • Price


18,153 shares
DKK 16,339,540.90
e)Date of the transaction2024-05-02
f)Place of the transactionCBOE EUROPE - DXE ORDER BOOKS (NL)


Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar
2 Reason for the notification
a)Position/statusExecutive Vice President
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

Identification codeNovo Nordisk B DK0062498333
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







Price(s)Volume(s)
DKK 900.142,800 shares
d)Aggregated information
  • Aggregated volume
  • Price


2,800 shares
DKK 2,520,380.90
e)Date of the transaction2024-05-02
f)Place of the transactionTURQUOISE EUROPE


Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar
2 Reason for the notification
a)Position/statusExecutive Vice President
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

Identification codeNovo Nordisk B DK0062498333
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







Price(s)Volume(s)
DKK 900.0010,437 shares
d)Aggregated information
  • Aggregated volume
  • Price


10,437 shares
DKK 9,393,300.00
e)Date of the transaction2024-05-02
f)Place of the transactionUBS EUROPE SE


Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar
2 Reason for the notification
a)Position/statusExecutive Vice President
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

Identification codeNovo Nordisk B DK0062498333
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







Price(s)Volume(s)
DKK 912.1511,051 shares
d)Aggregated information
  • Aggregated volume
  • Price


11,051 shares
DKK 10,080,130.60
e)Date of the transaction2024-05-02
f)Place of the transactionNASDAQ COPENHAGEN A/S

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Instagram, X, LinkedIn andYouTube.

Contacts for further information

Media:
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
Investors:
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

Sina Meyer
+45 3079 6656 azey@novonordisk.com

Company announcement No 36 / 2024

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Subsea7 awarded a contract for the Belinda field in the UK North Sea25.5.2024 14:01:09 CEST | Press release

Luxembourg – 25 May 2024 - Subsea7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a sizeable1 contract by Serica Energy, for the Belinda field development south-east of the Triton FPSO. The Belinda field is operated by Serica Energy and located approximately 190 kilometres east of Aberdeen in the UK Central North Sea, with a water depth of 95 metres. The contract scope includes project management, engineering, procurement, construction and installation (EPCI) of a 5-kilometre 8” production pipeline with a 3” piggy-backed gas lift line and an electro-hydraulic controls (EHC) umbilical. Subsea7’s scope also includes associated subsea structures and tie-ins to the Triton Floating Production Storage & Offloading (FPSO) vessel operated by Dana Petroleum, via an existing production manifold near the Triton riser base and for controls at the Evelyn valve skid. Project management and engineering work will commence immediately in Aberdeen. The offshore activities are scheduled

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio25.5.2024 12:15:00 CEST | Press release

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor,demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1 Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1 IgAN is a heterogeneous, progressive, rare kidney disease with a need for effective, targeted therapies6,7; up to 30% of patients with persistent proteinuria (≥1 g/day) progress to kidney failure within 10 years8 Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression Basel, May 25, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atr

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo25.5.2024 12:00:00 CEST | Press release

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2,3Fabhalta showed a favorable safety profile with no new safety signals1C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years4-7; currently there are no treatments approved for C3G7-9 Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, selectively targets the underlying cause of C3G1; late-stage development program ongoing across several other rare diseases10-13 Basel, May 25, 2024 – Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to support

Metasphere Labs Announces Development of Innovative Carbon Credit Protocol for Grid-Scale Batteries24.5.2024 22:05:00 CEST | Press release

VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is excited to announce an innovative initiative aimed at accelerating the decarbonization of the electricity grid through the development of a pioneering carbon credit protocol for grid-scale batteries. Innovative Carbon Credit Protocol The Company is committed to leveraging advanced technology to address critical environmental challenges. The new carbon credit protocol will enable grid-scale batteries to monetize their environmental attributes by generating carbon credits for the carbon reductions achieved through optimized battery operations. This protocol is designed to incentivize the deployment and operation of grid-scale batteries, ensuring they play a pivotal role in the transition to a clean energy future. Submission to Pure Sky Carbon Credit Registry The Company intends to submit this pr

Nokia Corporation: Repurchase of own shares on 24.05.202424.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 24 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 24.05.2024 Espoo, Finland – On 24 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,1533.55CEUX--BATE--AQEU--TQEX--Total362,1533.55 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

HiddenA line styled icon from Orion Icon Library.Eye